IDEAYA Biosciences Appoints New Director, Adjusts Executive Pay

Ticker: IDYA · Form: 8-K · Filed: Jun 27, 2025 · CIK: 1676725

Ideaya Biosciences, Inc. 8-K Filing Summary
FieldDetail
CompanyIdeaya Biosciences, Inc. (IDYA)
Form Type8-K
Filed DateJun 27, 2025
Risk Levelmedium
Sentimentneutral

Sentiment: neutral

Topics: executive-compensation, board-changes, employment-agreement

Related Tickers: IDYA

TL;DR

IDEAYA adds a director, boosts exec pay for Nakagawa & Park.

AI Summary

IDEAYA Biosciences, Inc. announced on June 26, 2025, changes in its board of directors and executive compensation. Specifically, Dr. Paul R. Hastings was appointed as a new director, and the company entered into new employment agreements with its Chief Executive Officer, Yujiro S. Nakagawa, and Chief Medical Officer, Dr. David M. Park. These agreements detail base salaries, potential bonuses, and equity awards.

Why It Matters

Changes in board composition and executive compensation can signal shifts in company strategy, governance, and future performance expectations.

Risk Assessment

Risk Level: medium — Changes in executive compensation and board appointments can indicate strategic shifts or potential future performance pressures.

Key Numbers

  • 650-443-6209 — Registrant's telephone number (Contact information for IDEAYA Biosciences, Inc.)

Key Players & Entities

  • IDEAYA Biosciences, Inc. (company) — Registrant
  • Dr. Paul R. Hastings (person) — Appointed Director
  • Yujiro S. Nakagawa (person) — Chief Executive Officer
  • Dr. David M. Park (person) — Chief Medical Officer
  • June 26, 2025 (date) — Date of earliest event reported

FAQ

Who was appointed as a new director for IDEAYA Biosciences, Inc.?

Dr. Paul R. Hastings was appointed as a new director.

What is the date of the earliest event reported in this 8-K filing?

The date of the earliest event reported is June 26, 2025.

What are the key executive positions mentioned in relation to new employment agreements?

The key executive positions are Chief Executive Officer (Yujiro S. Nakagawa) and Chief Medical Officer (Dr. David M. Park).

What is the principal executive office address of IDEAYA Biosciences, Inc.?

The address is 5000 Shoreline Court, Suite 300, South San Francisco, California 94080.

What is the Commission File Number for IDEAYA Biosciences, Inc.?

The Commission File Number is 001-38915.

Filing Details

This Form 8-K (Form 8-K) was filed with the SEC on June 27, 2025 by Dr. Paul R. Hastings regarding IDEAYA Biosciences, Inc. (IDYA).

View full filing on EDGAR

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.